Yuyu to appeal Fosamax Plus case to patent court

Published: 2007-12-19 06:59:00

Updated: 2007-12-19 06:59:00

Yuyu Pharm plans to file its lawsuit against MSD Korea to confirm the patent claims of Fosamax Plus in a patent court, after the Korean Intellectual Property Tribunal decided to reject Yuyu's claim that Fosamax Plus infringe on Maxmarvil (alendronate sodium plus calcitriol) patent.

Yuyu lodged...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK